R&D Tax Credits for Medical Device Manufacturing 2026: What Qualifies

Medical device manufacturing is one of the most R&D-intensive industries in the U.S. Companies spend years developing prototypes, testing materials, validating embedded software, and navigating FDA regulatory requirements.

Medical device R&D credits 2026 reward this work. Here is what qualifies and how to document it.

Important note on Section 174A domestic expensing: Under IRC Section 174A (enacted via the One Big Beautiful Bill Act), domestic R&D costs are once again 100% immediately deductible in the year incurred. Domestic research no longer requires 5-year amortization. (Note: Foreign research expenditures conducted outside the U.S. must still be capitalized and amortized over 15 years).

The Four-Part Test Applied to Medical Devices

To qualify, your activities must meet all four IRS requirements under IRC Section 41.

1. Permitted Purpose

Your work must aim to develop or improve a product, process, or software.

Examples:

• Designing a new implantable device

• Improving an existing surgical instrument

• Developing new sensor technology

• Creating custom manufacturing processes

2. Technological in Nature

The work must rely on engineering, biology, materials science, or computer science.

Examples:

• Biocompatibility testing of new materials

• Mechanical engineering of device components

• Embedded software development

• Electrical engineering for sensor systems

3. Elimination of Technical Uncertainty

You must face uncertainty about capability, method, or design at the project’s outset. This is a high bar—”trial and error” must be documented as systematic experimentation rather than routine testing.

What creates uncertainty:

• Unknown whether a material will meet biocompatibility requirements

• Uncertainty about whether a device can achieve necessary durability

• Questions about sensor accuracy in real-world conditions

• Doubt about manufacturing scalability

4. Process of Experimentation

You must show systematic evaluation through testing, prototyping, or trial and error.

Qualifying activities:

• Testing different material compositions

• Prototyping multiple device configurations

• Running iterative design-validation cycles

Failed experiments count. The IRS rewards experimentation, not just success.

What Qualifies in Medical Device Development

What Does Not Qualify

• Routine quality control: Standard testing of finished products without technical uncertainty

• Post-market surveillance: Routine monitoring of devices already on the market does not qualify unless it directly triggers a new engineering redesign to resolve a technical defect or failure

• Routine manufacturing: Standard production line activities without new development or process improvement

• Marketing and sales: Promotional activities or market research

• FDA submission preparation: Simply preparing submission documents or replicating existing lab work for compliance purposes does not qualify

Understanding medical device R&D credits 2026 also means knowing what does not qualify—routine QC, standard manufacturing without uncertainty, and purely administrative compliance work.

Which Expenses Qualify

The Regulatory Distinction That Matters

The key for medical device companies is separating R&D from regulatory compliance. Routine work performed solely to meet regulatory requirements does not qualify. But work that advances the state of the art while also generating regulatory data can qualify.

The distinction:

• Qualifying: Work that resolves technical uncertainty, even if the output supports a regulatory submission

• Not qualifying: Work that is purely clerical or administrative compliance activity

Example: A company running a clinical trial to test whether a new material meets biocompatibility standards is resolving technical uncertainty. A company simply preparing submission documents or replicating existing lab work for compliance purposes is not.

This is one of the most common points of IRS audit failure. The testing and engineering required to generate data for an FDA submission often qualifies, but the submission itself does not.

Documentation Best Practices

Medical device companies face unique documentation challenges because of the volume of testing and the complexity of R&D activities.

What to document:

• Design specifications and revision history

• Prototype build logs

• Test protocols and results (including failed tests)

• Biocompatibility and sterilization data

• Time tracking for engineers and technicians

• Contracts with CROs and testing labs

How to document it:

• Use project codes to separate R&D from routine QC and compliance work

• Ensure project management software (e.g., Jira, Azure DevOps) explicitly links employee time to specific “Technical Uncertainty” phases rather than general “Product Maintenance”

• Maintain version control for all design and software documentation

• Store all records in organized, accessible format

• Ensure documentation is contemporaneous (created during the work, not reconstructed later)

Section 174A & Foreign R&D Planning: Because domestic R&D costs can now be immediately expensed, businesses no longer face the tax-income squeeze caused by domestic amortization. However, if your medical device company uses offshore testing facilities or overseas CROs, those foreign R&D costs must still be amortized over 15 years.

State-level variation: State credits are highly volatile. For example, California’s R&D credit rules often differ slightly from federal treatment regarding what constitutes a “qualified expense.” Always verify state rules with a qualified tax professional.

State Programs for Medical Device Companies

Note: State caps, application windows, and rates are subject to annual legislative updates. Verify current figures with a qualified tax professional.

Bottom Line

Medical device R&D credits 2026 are one of the most valuable incentives for an industry that invests heavily in innovation. Prototype development, material testing, embedded software, and process design can all qualify.

The combination of immediate domestic R&D expensing under Section 174A and federal R&D credits under Section 41 makes 2026 one of the most advantageous tax years for medical device innovation. State programs add even more value, though rules vary by jurisdiction.

Call (844) 463-2400 or email hello@indagotax.com to discuss which activities in your medical device company qualify.